Cytrellis’ first product, ellacor, is a novel, proprietary system with Micro-Coring technology designed to remove excess skin associated with aging without invasive surgery or evidence of scarring.
Location: United States, Massachusetts, Woburn
Employees: 11-50
Phone: +1 857-254-1720
Total raised: $78.5M
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | PFM Health... | pfmhealths... |
| 17.07.2021 | ARCH Ventu... | archventur... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.09.2021 | Series C | $50M | - |
| 05.06.2018 | Series B | $28.5M | - |
Mentions in press and media 11
| Date | Title | Description |
| 11.04.2024 | Cytrellis to Present at the Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) | WOBURN, Mass., April 11, 2024 /PRNewswire/ -- Cytrellis Biosystems, a pioneer in novel medical aesthetic solutions, announced today that clinical data related to ellacor® and its proprietary Micro-Coring® Technology will be presented during... |
| 22.09.2021 | Cytrellis Biosystems Closes $50M Series C Financing | Cytrellis Biosystems, a Woburn, Mass.-based medical technology company dedicated to the development and commercialization of aesthetic devices which emphasize safety, efficacy, and improved quality of life for patients, closed a $50m Series... |
| 21.09.2021 | Why dealmaking in the sports betting and online gambling world is currently insane | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content How to empower women employees through the pandemic From Capital One Just a few year... |
| 21.09.2021 | Why dealmaking in the sports betting and online gambling world is currently insane | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Just a few years ago, sports betting sat in a legally dubious place in the U.S. That was until th... |
| 21.09.2021 | Cytrellis Biosystems Nabs $50M Series C Round | WOBURN, MA, Cytrellis today announced the closing of a $50 million Series C funding round. >> Click here for more funding data on Cytrellis Biosystems >> To export Cytrellis Biosystems funding data to PDF and Excel, click he... |
| 27.07.2021 | Cytrellis Announces FDA Clearance for Breakthrough ellacor™ Micro-Coring™ Technology | |
| 06.06.2018 | Term Sheet — Wednesday, June 6 | 5 Qs WITH A DEALMAKER Founders Fund partner Trae Stephens found his way to venture capital from the public sector. Paid Content How can you protect what you can't see? From ExtraHop “I was a senior in high school when 9/11 happened and want... |
| 05.06.2018 | Cytrellis Biosystems Completes $28.5 Million Series B Financing | Cytrellis Biosystems, Inc., a medical technology company developing a new, proprietary class of dermatologic aesthetic devices for the reduction of skin laxity, today announced that it has received $28.5 million in a Series B round which in... |
| 05.06.2018 | Cytrellis Biosystems Raises $28.5M in Series B Financing | Cytrellis Biosystems, Inc., a Woburn, Mass.-based medical technology company developing a new, proprietary class of dermatologic aesthetic devices for the reduction of skin laxity, received $28.5m in Series B funding. Backers included exist... |
| 05.06.2018 | Cytrellis Biosystems Nabs $28.5M | WOBURN, MA, Cytrellis Biosystems today announced that it has received $28.5 million in a Series B round. >> Click here for more funding data on Cytrellis Biosystems >> To export Cytrellis Biosystems funding data to PDF and E... |
Show more